news details |
|
|
| Dr Vishal Tandon from Jammu nominated as national faculty by ISRPT | | | 
Early Times Report
JAMMU, Nov 27: Dr. Vishal R Tandon from GMC, Jammu has been nominated as national faculty to frame evidence based national treatment guidelines of most common diseases like hypertension, diabetes mellitus, dyslipidaemia and COVID-19 for the prestigious Indian Society of Rational Pharmaco-therapeutics (ISRPT).
These guidelines shall be framed as per the existing level of scientific evidence and grade of recommendations in their favour with the help of leading clinicians and pharmacologist of repute from the country who shall serve as guest faculty. Dr. H S Reehan, Director Professor Pharmacology, Lady Hardinge Medical College, New Delhi and Dr. Tandon, Professor, GMC Jammu shall be finally editing and compiling these national treatment guidelines for the society after series of deliberations at national level in form of the book, which shall also be published in leading journal for wider utility of practitioners.
Dr Tandon was also the invited faculty/chairperson in recently held prestigious 13th National Conference of ISRPT, 2021 held at Indore. He chaired various session “Clinical trials in COVID-19; Accelerated Preclinical Paths for Rapid development of COVID Therapies and Pragmatic Clinical Trials”. He also delivered an invited guest lecture on drug safety “art of medical content writing of adverse drug reactions”. He was also a judge in Poster Presentation where various original studies were presented by the research scholars of the country.
In his lecture he stressed to maintain Good pharmaco-vigilance practices and provide complete medical information of the adverse drug reaction for speedy generation of drug signal /alerts so that drug safety can be enhanced for the patients. He proposed to start a national certification course in drug safety and rational drug prescription at national level by the society in coloration with drug regulatory authorities and Indian Pharmacopeia Commission, Government of India and WHO, to deal with problems of under reporting and incomplete information of ADRs presently reported in the national programme and deal with the problem of irrational drug prescription at the country level. |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| |
|
|
|
|
 |
|
|
|
|
STOCK UPDATE |
|
|
 |
| BSE
Sensex |
 |
| NSE
Nifty |
|
|
| |
CRICKET UPDATE |
|
|
|
|
| |
| |
|
|
| |
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
